Barclays Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $925
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Overweight rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $900 to $925.
August 21, 2023 | 10:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Regeneron Pharmaceuticals and raises the price target from $900 to $925, which could positively impact the stock.
The raised price target by Barclays indicates a positive outlook for Regeneron Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100